Vetter Marks the Start of New Clinical Site Construction with Groundbreaking Ceremony
Vetter continues to expand in the US
Vetter celebrated the start of construction on its new clinical manufacturing site in the Chicago area with an official groundbreaking ceremony. The state-of-the-art facility, which is being built in Des Plaines, Illinois, is expected to be ready for media fill by the end of 2029. This $285 million investment will strengthen Vetter’s position as a leading global partner for aseptic manufacturing in early clinical development.
The new site provides additional capacity for small-batch production of novel active ingredients and includes space for warehouses, laboratories, and administrative offices. The approximately 860,000 square feet site has the capacity to accommodate future expansion, contingent on global demand and additional strategic investments.
"This project marks another milestone in our international growth strategy. It underscores our commitment to quality and innovation, as well as our responsibility to our customers, partners, and patients around the world," Senator h.c. Udo J. Vetter, Chairman of the Advisory Board.
With its new location, Vetter is strengthening its presence in the North American market and supplementing its existing clinical network in Skokie, Illinois and Rankweil, Austria.
Most read news
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.